Lewis K - Search Results

1

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.

Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Ribas A, et al. Among authors: lewis k. J Transl Med. 2012 Nov 21;10:236. doi: 10.1186/1479-5876-10-236. J Transl Med. 2012. PMID: 23171508 Free PMC article. Clinical Trial.

2

A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.

Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R. Lewis KD, et al. Cancer Invest. 2005;23(4):303-8. doi: 10.1081/cnv-58832. Cancer Invest. 2005. PMID: 16100942 Clinical Trial.

3

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.

Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS. Koyanagi K, et al. Among authors: lewis k. J Clin Oncol. 2005 Nov 1;23(31):8057-64. doi: 10.1200/JCO.2005.02.0958. J Clin Oncol. 2005. PMID: 16258104 Free PMC article.

4

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. Lewis KD, et al. Invest New Drugs. 2006 Jan;24(1):89-94. doi: 10.1007/s10637-005-4544-y. Invest New Drugs. 2006. PMID: 16379038 Clinical Trial.

5

Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass.

Lewis KD, Dollarhide S, Fitzpatrick JE, Gonzalez R, High WA, McCarter MD, Olsen C, Raben D. Lewis KD, et al. Oncology (Williston Park). 2006 Jun;20(7):763-70. Oncology (Williston Park). 2006. PMID: 16841798 Free article. No abstract available.

6

Metastatic melanoma in the breast: a report of 27 cases.

Ravdel L, Robinson WA, Lewis K, Gonzalez R. Ravdel L, et al. Among authors: lewis k. J Surg Oncol. 2006 Aug 1;94(2):101-4. doi: 10.1002/jso.20592. J Surg Oncol. 2006. PMID: 16847918

7

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. Lewis KD, et al. Invest New Drugs. 2008 Feb;26(1):89-94. doi: 10.1007/s10637-007-9080-5. Epub 2007 Sep 20. Invest New Drugs. 2008. PMID: 17891338 Clinical Trial.

8

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. McDermott DF, et al. Among authors: lewis k. J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288. J Clin Oncol. 2008. PMID: 18445842 Clinical Trial.

9

PI-88: a novel inhibitor of angiogenesis.

Kudchadkar R, Gonzalez R, Lewis KD. Kudchadkar R, et al. Expert Opin Investig Drugs. 2008 Nov;17(11):1769-76. doi: 10.1517/13543784.17.11.1769. Expert Opin Investig Drugs. 2008. PMID: 18922112

10

Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature.

Fujita M, High WA, Asgari S, Lewis KD, Gonzalez R. Fujita M, et al. Int J Dermatol. 2009 Apr;48(4):426-30. doi: 10.1111/j.1365-4632.2009.03987.x. Int J Dermatol. 2009. PMID: 19335434

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,472 results

Search Page